Emerging biopharma companies – those that are at clinical or commercial stage with less than $1bn in revenues – are driving more new drug approvals in 2021 than in the past, according to analysis by BIO.
"We potentially have the highest number of small companies driving the approvals this year," BIO VP-industry research David Thomas said during a presentation on emerging company trends on